The follow-through. I took the trade.

Two weeks ago, I titled my review The alert fired. I didn't buy.

I had spent a weekend tearing through ACN — Accenture. It passed eleven of my twelve fundamental gates, had pristine free cash flow, and traded at half its historical multiple. But momentum was still drifting down (NMS 4), so I sat on my hands and waited for real confirmation.

Three days later, the chart delivered. ACN broke its downtrend line on top of the strategy setup, giving me the green light to buy at $152.13. Six days later, when the strategy flashed a sell signal and I worried about a false breakout, I closed the position at $161.98 for a clean +6.47% swing gain.

Waiting on July 25 was discipline. Buying on the trend break on July 28 was execution. And stepping off when the sell signal fired was risk management. Here is how that trade unfolded, what happened to the rest of the book, and how we upgraded our research engine this week.

The ACN sequel: trend break in, strategy sell out

When you run a rules-based system, patience is half the job. The other half is acting decisively when your criteria line up — and respecting the exit when caution creeps back in.

On July 21, two TradingView strategies had flagged Accenture as a buy candidate, but price action was still in a waterfall. On July 28, the picture changed: ACN put in a decisive trend break across its downtrend, confirming the earlier strategy signals. That technical breakout gave me the missing piece of confirmation I needed. I bought at $152.13.

The trade worked right away. The stock pushed up through $160 over the next several sessions. But on Monday, August 3, the strategy fired an exit signal.

I had a choice: hold out for more upside, or protect the capital. With the stock rebounding rapidly off a severe downtrend, I was worried this move might turn out to be a false breakout. Rather than argue with the strategy's sell signal or hope for continuation, I obeyed the system and closed the entire position at $161.98.

The takeaway isn't just the profit. It's the process: waiting when the momentum wasn't ready on July 21, taking the trade when the trend break confirmed on July 28, and respecting the exit signal on August 3 when false-breakout risk surfaced.

Holding through multiple compression: MA & MSFT

While ACN gave us a quick tactical win, the core equity book saw significant action. This fortnight, the portfolio advanced +3.09% on the adjusted curve.

A lot of that was driven by a violent snapback in Big Tech. MSFT rocketed +31.0% over the window back to $499.99, while PLTR rallied +39.9%.

I pulled the full Stock Rover deep research reports on two of our cornerstone holdings this week — MA (Mastercard) and MSFT (Microsoft) — to test whether we should drop or trim either name.

Here is what the actual business numbers say:

1. Mastercard (MA): Multiple compression vs. business decay

Over the past twelve months, Mastercard has lagged the S&P 500 by -24% (delivering just +0.9% vs. the market's +23.6%). If you only look at the stock chart, you might think the thesis is broken.

When you open the financial statements, the reality is the exact opposite:

• Moat & Efficiency: Gross margin of 78.1%, operating margin of 59.8%, and Return on Invested Capital (ROIC) of 56.2%.¹
• Growth: Sales grew +16.0% YoY ($35.1B), and EPS grew +22.6% ($18.18). Forward EPS is modeled to reach $22.97.
• Earnings Reliability: Positive earnings surprises in 11 of the last 12 quarters (>91% beat rate).

Why did the stock tread water for a year? Its P/E multiple compressed from 39.3x down to 31.0x (and 24.5x forward). In other words: the business grew ~20%, while the stock digested its premium valuation.

Selling a 56% ROIC monopoly at the bottom of a multiple compression cycle is a classic retail mistake. Mastercard remains a Conviction Hold.

2. Microsoft (MSFT): Sizing vs. AI CapEx

Microsoft trades at 27.9x P/E (21.3x forward) with a Quality Score of 99/100. TTM sales hit $331.8B (+17.8%) and net income reached $133.7B (+14.7%).

The only metric that looks stretched is Price/FCF (55.6x). That is not operational leakage: Microsoft deployed $115.9B in capital expenditures over the past four quarters (+41.9% CAGR since 2022) to build out global Azure AI infrastructure. Operating cash flow grew +18.5% to a record $182.9B.

In our LIRA, Microsoft is up +42.8% from our cost basis. Unless you are rebalancing single-stock concentration risk to fund underweighted sectors, the forward earnings power ($23.47 EPS next year) warrants holding the core position.

Gold and resources do their job

Precious metals and natural resource holdings provided strong diversification. AEM (Agnico Eagle) surged +23.2% and NEM (Newmont) jumped +21.2%, helping absorb pullbacks in cyclicals like FTI (-9.3%) and CF (-8.6%).

This is why we keep structural resource hedges in the book: when growth multiples wobble, gold cashflows steady the boat.

How the portfolio did

Up +3.09% on the adjusted curve — stripped of background DRIPs and cash contributions.

The curve dipped mid-period around July 28–30 during the tech rotation, before climbing steadily into early August as earnings beats and the gold rebound took hold.

Scaling the research engine: AI deep-dives

Beyond the trades, this week marked a major operational milestone for our screener infrastructure.

We processed all 60 names across our quantitative funnels (Bedrock, Prospector, Quantum) and established an 8-stock shortlist: TEL, CVE, INTU, GILD, NEM, FTI, NFLX, and PSA, along with top energy candidate VLO.

We then ran all nine names through our deep-dive pipeline. This engine runs Gemini 3.1 Pro to evaluate structural competitive advantages, test Pat Dorsey moat criteria (switching costs, network effects, cost advantages, intangible assets), and set explicit, falsifiable sell conditions.

Every single deep-dive generated a published investment memo in sr-reports/, updated the wiki position dossier, and synchronized live to the database cards on moneymark.io/screener.

What's next

1. Shortlist monitoring: Keep close watch on CVE (Cenovus) and VLO (Valero) for technical entry triggers in the energy sleeve.
2. Gilead (GILD): High-confidence moat with expanding oncology/HIV cashflows — ready to add if price confirms.
3. Patience on tech: Let the mega-caps compound without chasing extended breakouts.

Two weeks ago we waited. This week we executed, held the quality core, and upgraded the entire research stack.

— Mark

Footnotes

1. Stock Rover — Mastercard Inc. (MA) Research Report (August 8, 2026). Financial statements, ROIC, and 5-year valuation history.
2. Stock Rover — Microsoft Corp. (MSFT) Research Report (August 8, 2026). CapEx acceleration, cash flow breakdown, and segment earnings estimates.

— Mark